MM-464 LocoMMotion: A Prospective, Observational, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed/Refractory Multiple Myeloma – Final Analysis at 2-Year Follow-up

• Published in: Clinical lymphoma, myeloma and leukemia Vol. 23; pp. S500 - S501
• Main Authors: Moreau, Philippe, Weisel, Katja, de Stefano, Valerio, Goldschmidt, Hartmut, Delforge, Michel, Mohty, Mohamad, Lindsey-Hill, Joanne, Dytfeld, Dominik, Angelucci, Emanuele, Vincent, Laure, Perrot, Aurore, Benjamin, Reuben, van de Donk, Niels, Ocio, Enrique, Groen-Damen, Ester in ‘t, Roccia, Tito, Schecter, Jordan, Haddad, Imène, Strulev, Vadim, Mitchell, Lada, Buyze, Jozefien, Saarinen, Silva, Filho, Octavio Costa, Einsele, Hermann, Mateos, María-Victoria
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01.09.2023
• Subjects: CAR-T cell therapy; standard of care; triple-class exposed; MM; standard of care; triple-class exposed; CAR-T cell therapy
• ISSN: 2152-2650; 2152-2669
• DOI: 10.1016/S2152-2650(23)01455-6

LocoMMotion (NCT04035226), the first prospective observational study assessing the effectiveness and safety of real-life standard of care (SOC) treatments for triple-class–exposed (TCE) patients with relapsed/refractory multiple myeloma (RRMM), demonstrated poor response and short survival (median follow-up: 16.1 months). To report LocoMMotion final analysis. Adult TCE patients with MM and progressive disease (PD) since the last line of therapy (LOT) who were double refractory to a proteasome inhibitor and immunomodulatory drug or had ≥3 prior LOT. Patient-level data and treatment choice were collected for 24 months after the first index LOT dosing of the last enrolled patient from August 2019 to October 2022. Primary endpoint was overall response rate (ORR); secondary endpoints included additional efficacy endpoints and safety. Median follow-up (N=248) was 26.4 (95% CI, 25.0-28.1) months. The median (range) age was 68 (41-89) years; 135 patients (54.4%) were male. Patients received a median (range) of 4 (2-13) prior LOT, 182 (73.4%) were triple-class refractory, and 229 (92.3%) were refractory to the last LOT. Ninety-one unique treatment regimens were used in index LOT. The median (range) treatment duration (mTD) was 4.0 (0.1-33.6) months. ORR (95% CI) was 31.9% (26.1%-38.0%); the median (95% CI) duration of response was 7.4 (4.9-11.1) months. Median (95% CI) progression-free survival (PFS) and overall survival (OS) were 4.6 (3.9-5.6) and 13.8 (10.8-17.0) months, respectively. Twelve- and 24-month PFS and OS rates (95% CI) were 21.0% (15.3%-27.3%) and 10.5% (6.1%-16.3%), respectively, and 53.4% (46.7%-59.6%) and 33.7% (27.3%-40.2%), respectively. One-hundred fifty-two patients (61.3%) had subsequent LOT; 79 different regimens were used (mTD [range], 2.8 [0-29.7] months). B-cell maturation antigen–targeted therapies increased from index LOT (2.8%) to subsequent LOT (24.2%). During index LOT, 86.7% of patients experienced an adverse event, most commonly cytopenias. Thirteen patients (5.2%) developed a second primary malignancy (index LOT, n=5; subsequent LOT, n=8). One-hundred fifty-eight patients (63.7%) died (67.7% and 15.8% of deaths due to PD and adverse events, respectively). TCE patients with RRMM have poor survival, rapid PD, and a lack of well-established SOC.